Insider Selling: Biodesix, Inc. (NASDAQ:BDSX) Insider Sells 5,862 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSXGet Free Report) insider Gary Anthony Pestano sold 5,862 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $1.92, for a total value of $11,255.04. Following the transaction, the insider now owns 128,272 shares of the company’s stock, valued at approximately $246,282.24. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Gary Anthony Pestano also recently made the following trade(s):

  • On Monday, February 12th, Gary Anthony Pestano sold 5,022 shares of Biodesix stock. The shares were sold at an average price of $1.66, for a total value of $8,336.52.

Biodesix Price Performance

Shares of NASDAQ BDSX traded down $0.20 during midday trading on Monday, hitting $1.65. The stock had a trading volume of 308,617 shares, compared to its average volume of 146,058. The company’s 50-day simple moving average is $1.84 and its 200 day simple moving average is $1.63. The firm has a market cap of $149.29 million, a P/E ratio of -1.83 and a beta of 1.24. Biodesix, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $2.45.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDSX. William Blair reiterated an “outperform” rating on shares of Biodesix in a research report on Wednesday, November 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $3.50 price objective on shares of Biodesix in a research report on Thursday, December 7th. Finally, Wedbush reiterated an “outperform” rating on shares of Biodesix in a research report on Wednesday, November 15th.

View Our Latest Research Report on BDSX

Institutional Investors Weigh In On Biodesix

Several hedge funds and other institutional investors have recently made changes to their positions in BDSX. Renaissance Technologies LLC acquired a new stake in shares of Biodesix in the 2nd quarter valued at $93,000. Vanguard Group Inc. increased its stake in shares of Biodesix by 33.1% in the 3rd quarter. Vanguard Group Inc. now owns 239,656 shares of the company’s stock valued at $305,000 after buying an additional 59,660 shares during the period. CI Private Wealth LLC acquired a new stake in shares of Biodesix in the 4th quarter valued at $57,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Biodesix in the 1st quarter valued at $38,000. Finally, Blair William & Co. IL increased its stake in shares of Biodesix by 151.5% in the 1st quarter. Blair William & Co. IL now owns 49,800 shares of the company’s stock valued at $93,000 after buying an additional 30,000 shares during the period. 21.24% of the stock is owned by institutional investors and hedge funds.

Biodesix Company Profile

(Get Free Report)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Recommended Stories

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.